

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/462,094	01/11/2000	PETER K.T. PANG	P8061-9012	4670
759	90 12/24/2002			
ARENT FOX KINTNER PLOTKIN & KAHN, PLLC 1050 Connecticut Avenue, N.W. Suite 600 Washington, DC 20036-5339			EXAMINER	
			BORIN, MICHAEL L	
			ART UNIT	DARED MUMBER
			ARTUNIT	PAPER NUMBER
			1631	19
			DATE MAILED: 12/24/2002	10

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/462,094 Applicant(s)

Pang et al.

Examiner

Michael Borin

Art Unit 1631



	The MAILING DATE of this communication appears	on the cover sheet with the correspondence address			
	for Reply				
	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION.	TO EXPIRE 3 MONTH(S) FROM			
		no event, however, may a reply be timely filed after SIX (6) MONTHS from the			
mailing	g date of this communication. period for reply specified above is less than thirty (30) days, a reply within th				
- If NO		and will expire SIX (6) MONTHS from the mailing date of this communication.			
- Any re	pply received by the Office later than three months after the mailing date of t				
Status	l patent term adjustment. See 37 CFR 1.704(b).				
1) 💢	Responsive to communication(s) filed on Oct 15, 2				
2a) 💢	This action is FINAL . 2b) ☐ This act				
3) 🗆	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.				
Disposi	tion of Claims				
4) 💢	Claim(s) <u>1 and 3-20</u>	is/are pending in the application.			
4	la) Of the above, claim(s) <u>3-6, 9-14, and 16-18</u>	is/are withdrawn from consideration.			
5) 🗆	Claim(s)	is/are allowed.			
	Claim(s) <u>1, 7, 8, 15, 19, and 20</u>				
	Claim(s)				
8) 🗆		are subject to restriction and/or election requirement.			
Applica	ition Papers				
9) 🗆	The specification is objected to by the Examiner.				
10)	The drawing(s) filed on is/are	a) \square accepted or b) \square objected to by the Examiner.			
	Applicant may not request that any objection to the d				
11)	The proposed drawing correction filed on	is: a) \square approved b) \square disapproved by the Examiner.			
	If approved, corrected drawings are required in reply t				
12) The oath or declaration is objected to by the Examiner.					
	under 35 U.S.C. §§ 119 and 120				
13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a)	☐ All b)☐ Some* c)☐ None of:				
1. \square Certified copies of the priority documents have been received.					
	2. Certified copies of the priority documents have been received in Application No				
;	 Copies of the certified copies of the priority de application from the International Bures 	ocuments have been received in this National Stage			
*S	ee the attached detailed Office action for a list of the				
14) 🗌	Acknowledgement is made of a claim for domestic	priority under 35 U.S.C. § 119(e).			
a) \square The translation of the foreign language provisional application has been received.					
15)∐	Acknowledgement is made of a claim for domestic	priority under 35 U.S.C. §§ 120 and/or 121.			
Attachm					
	tice of References Cited (PTO-892)	4) Unterview Summary (PTO-413) Paper No(s).			
	ormation Disclosure Statement(s) (PTO-1449) Paper No(s).	5) Notice of Informal Patent Application (PTO-152)			
3/	biniation Disclosure Statement(s) (P10-1449) Paper No(s)	6) Uther:			

Serial Number: 09/462094 Page 2

Art Unit: 1631

DETAILED ACTION

Status of Claims

- 1. Amendment filed 10/15/02 is acknowledged. Claim 2 is canceled. Claims 19,20, which replace the canceled claim 2, are added. Claims 1, 3-20 are pending. Claims 3-6,9-13,14,16-18 remain withdrawn from consideration, as being drawn to a non-elected groups.
- 2. Rejection of claim 2 under 35 U.S.C. 112, second paragraph, is withdrawn in view of cancellation of the claim.

Claim Rejections - 35 USC § 102 and 103.

3. Rejection of claims 1,7 under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C.103(a) as obvious over Dupont et al (US Patent 5,618,925) is maintained for the reasons of record.

Applicant's arguments about effect of lyophilization are noted but are not deemed convincing. First, the reference discloses variety of extracts obtained from shark cartilage, not necessarily subject to lyophilization. See, e..g., paragraph bridging columns 2 and 3 (col. 3, lines 14,15, in particular), and col. 3, lines 25-29. Second,

Serial Number: 09/462094 Page 3

Art Unit: 1631

the instant claims are not limited to any particular physical state of the extract, and read equally on solid and liquid extracts.

In regard to the anti-PTH activity of the extract, as was discussed in the previous Office action, it has been held that where applicant claims a composition in terms of function, property or characteristic where said function is not explicitly shown by the reference and where the examiner has explained why the function, property or characteristic is considered inherent in the prior art, it is appropriate for the examiner to make a rejection under both the applicable section of 35 USC 102 and 35 USC 103 such that the burden is placed upon the applicant to provide clear evidence that the respective compositions do in fact differ. No showing that extracts taught in Dupont do not have anti-PTH activity has been provided in applicant's response.

4. Claims 15, 19,20 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C.103(a) as obvious over Dupont et al (US Patent 5,618,925). The rejection is maintained for the reasons of record as applied to claims 2,15 in the previous Office action (paragraph #6).

Applicant argues that "in the present invention the supernatant is lyophilized".

No lyophilization step was identified in the instant claims.

Serial Number: 09/462094 Page 4

Art Unit: 1631

5. Claim 8 remains rejected under 35 U.S.C.103(a) as obvious over Halperin et al (US Patent 5,512,591) and Dupont et al (US Patent 5,618,925). The rejection is

maintained for the reason of record.

Applicant argues that Halperin does not disclose shark extract which retains activity after lyophilization. As discussed in the previous paragraph, the instant claims

do not describe lyophilization step either.

Conclusion.

6. No claims are allowed

7. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time

policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE

MONTHS from the mailing date of this action. In the event a first reply is filed within

TWO MONTHS of the mailing date of this final action and the advisory action is not

mailed until after the end of the THREE-MONTH shortened statutory period, then the

shortened statutory period will expire on the date the advisory action is mailed, and

any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing

Serial Number: 09/462094

Art Unit: 1631

date of the advisory action. In no event, however, will the statutory period for reply

Page 5

expire later than SIX MONTHS from the mailing date of this final action.

8. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Michael Borin whose telephone number is (703)

305-4506. Dr. Borin can normally be reached between the hours of 8:30 A.M. to

5:00 P.M. EST Monday to Friday. If attempts to reach the examiner by telephone are

unsuccessful, the examiner's supervisor, Mr. Michael Woodward, can be reached on

(703) 308-4028. The fax telephone number for this group is (703) 305-3014.

Any inquiry of a general nature or relating the status of this application should

be directed to the Group receptionist whose telephone number is (703) 308-0196.

MICHAEL BORIN, PH.D. PRIMARY EXAMINER

December 20, 2002

mlb